Physician profile
John C Lyne
NPI 1306943477
$3,109.46
in general payments reported to CMS, 2019-2025
11 companies · $400 in 2025
The $400 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64.42 · 2020: $1,806 · 2021: $107 · 2022: $412 · 2023: $92.57 · 2024: $228 · 2025: $400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $711 · Travel and Lodging: $9.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $711.26 |
| Travel and Lodging | $9.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,788.00 | 2020 | |
| Procept Biorobotics Corporation | $363.06 | 2024-2025 | Aquabeam System |
| Teleflex LLC | $247.73 | 2021-2022 | |
| Boston Scientific Corporation | $232.11 | 2022-2023 | |
| Janssen Scientific Affairs, LLC | $161.59 | 2025 | Erleada |
| Intuitive Surgical, INC. | $103.28 | 2025 | |
| Astellas Pharma US INC | $96.53 | 2019-2023 | Myrbetriq |
| Ambu INC. | $44.76 | 2022 | |
| Laborie Medical Technologies Corp. | $33.62 | 2023 | |
| Innovation Technologies INC | $26.61 | 2023 | Irrisept |
| Baxter Healthcare | $12.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Lyne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.